Celebrex May Slow, Prevent Skin Cancers

109 7
Celebrex May Slow, Prevent Skin Cancers Jan. 5, 2009 -- There is mounting evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) may help prevent or slow the growth of non-melanomaskin cancers.

In a study published today, the Cox-2 arthritis drug Celebrex was found to reduce the growth of basal cell skin cancers by 50% in some patients with a rare genetic condition that makes them highly susceptible to the tumors.

And in a separate study reported last May, people who took Celebrex daily for nine months had 60% fewer non-melanoma skin cancers than people who did not take the drug.

Celebrex and other Cox-2 inhibitors act on the cyclooxygenase-2 enzyme involved in inflammation.

Stanford University assistant professor of dermatology Jean Y. Tang, MD, PhD, says the findings suggest a role for the cyclooxygenase enzyme in the development of basal cell carcinoma and possibly other non-melanoma skin cancers.

"Basal cell carcinomas are the most common cancer in the United States," she says. "Even though these tumors are not lethal they can have a big impact on quality of life, and we have no way to treat them short of surgical removal."


Assess Your Risk for the 5 Most Common Cancers
Source...
Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.
You can unsubscribe at any time

Leave A Reply

Your email address will not be published.